Boston Scientific and Abbott Laboratories Lead the Global Drug Eluting Stents Market: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- The global drug eluting stents market was valued at $4.6 billion in 2010, according to a new report available on companiesandmarkets.com. The market was estimated at $1.69 billion in 2003 and has registered a CAGR of 15.4% between 2003 and 2010. It is expected to remain stagnant in the future due to decreasing average selling prices. However the volumes are expected to increase due to the higher adoption of drug eluting stents.

Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
http://www.companiesandmarkets.com/Market-Report/drug-eluting-stents-global-pipeline-analysis,-competitive-landscape-and-market-forecasts-to-2017-670877.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The US was estimated as the largest drug eluting stents market with a value of about $2 billion in 2010. The US DES market increased from $1.1 billion in 2003 to $2 billion in 2010 at a CAGR of 8.6%. The revenue increase was due to the wide acceptance of DES by physicians in the US.

In 2010, the prevalence of coronary heart disease in the US was 8%. According to the National Health and Nutrition Examination Survey 2005-2008 data, about 16.3 million adults were suffering from coronary heart disease in the US. 800,000 people will suffer from a new coronary attack annually, while 500,000 will suffer a recurring one. At the current rate, the prevalence of the disease will rise to 9.3% by 2030 and lead to an increase of eight million patients suffering with coronary heart disease.

In 2010, Boston Scientific reported revenues of $1.5 billion in 2010 and held a 33.4% market share in the DES market. Boston Scientific reported a decline in sales by 11%. Sales from the TAXUS and the PROMUS Drug Eluting Stents have helped Boston Scientific retain its market leader position.

Abbott Laboratories recorded sales of $1.4 billion and held a market share of 31%. The XIENCE Everolimus drug eluting stent has contributed towards Abbott's success. The introduction of the Absorb Bioabsorbable drug eluting stent will further aid Abbott in gaining significant share in the DES market.

Report Details: http://www.companiesandmarkets.com/Market-Report/drug-eluting-stents-global-pipeline-analysis,-competitive-landscape-and-market-forecasts-to-2017-670877.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44(0) 203 086 8600

KEYWORDS:   United Kingdom

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Communications  Other Communications  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…